BioArctic AB

Stocks

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 02:06:10 10/07/2026 pm IST			5-day change	1st Jan Change
327.90 ^SEK	-0.03%		-0.48%	+5.86%

08/07	Lancelot Sweden fell 0.8% in June, BioArctic slid despite Eli Lilly deal	FW
01/07	Alzecure CEO on the multibillion-dollar deal: 'QuantumCell can get products to market quickly'	FW

Three Nasdaq Stockholm companies trade ex-dividend today

Published on 05/29/2026 at 09:43 am IST

Finwire - Translated by Marketscreener - See original

Add MarketScreener to your sources

BIOARCTIC AB

-0.03%

AROS BOSTADSUTVECKLING AB

+6.62%

Three companies listed on Nasdaq Stockholm are trading ex-dividend today, May 29, as follows.

* Besqab: SEK 1.87 per Class B preferred share (annualized dividend of SEK 7.50)
* Bioarctic: SEK 2.00 per share
* Stenhus Fastigheter: SEK 0.16 per share (annualized dividend of SEK 0.31)

Add MarketScreener to your sources

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Off-Hours Price	Change	5-day change	Capi.
	BIOARCTIC AB	327.90SEK	-0.03%	-0.48%	301.21Cr
	AROS BOSTADSUTVECKLING AB	29.00SEK	+6.62%	+1.05%	29Cr

Latest news about BioArctic AB

08/07	Lancelot Sweden fell 0.8% in June, BioArctic slid despite Eli Lilly deal	FW
01/07	Alzecure CEO on the multibillion-dollar deal: 'QuantumCell can get products to market quickly'	FW
30/06	Indecap Guide Q30 rose 3.8 percent in May, Sinch posts strong gains	FW
30/06	Indecap Sverige rose 3.3% in May, steady gains despite mixed earnings picture	FW
30/06	Bioarctic: New Leqembi Data to Be Presented at AAIC 2026	FW
22/06	Hemnet Slips in Stockholm, OMXS30 Index Rises 0.4%	FW
22/06	Down in Stockholm, OMXS30 index slips 0.7%	FW
22/06	Eli Lilly, BioArctic Sign Neurodegeneration Research Deal Worth Up to $800 Million	MT
22/06	BioArctic AB And Eli Lilly And Company Sign Research And Collaboration Agreement Combining Lilly Compound With BioArctic's BrainTransporter Technology	CI
22/06	EasyJet Stays Aloft, Babcock Takes On Water
22/06	RX Securities reiterates buy on BioArctic after Eli Lilly deal, commissioned research	FW
22/06	Stockholm's stock market opens Monday lower, OMXS30 index down 0.7 percent	FW
22/06	Stockholm exchange seen opening mixed on Monday	FW
22/06	BioArctic Signs Research, Collaboration Pact With Eli Lilly	DJ
22/06	BioArctic Signs Collaboration with Eli Lilly on Potential New Treatment for Neurodegeneration	MT

Chart BioArctic AB

Duration

Period

BIOA B: Dynamic Chart

Company Profile

BioArctic AB is a Swedenâ€‘based biopharmaceutical company specializing in the discovery and development of diseaseâ€‘modifying treatments for neurodegenerative disorders. The Companyâ€™s primary focus is on conditions that affect the central nervous system (CNS), including Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis (ALS), areas characterized by high unmet medical need and limited effective therapies. BioArctic AB conducts advanced research and development of innovative biological drugs, with a particular emphasis on monoclonal antibodies designed to target the underlying disease mechanisms rather than only alleviating symptoms. The Company combines inâ€‘house scientific expertise with strategic collaborations with global pharmaceutical partners to advance and commercialize its therapeutic candidates worldwide.

Employees

141

Sector

Biotechnology & Medical Research

Calendar

23/07 - Earnings release - Q2 2026

More about the company